Milan Chheda, MD
Medical Oncology · Saint Louis, MONPI 1902852494
Payments from drug & device makers
What this record shows
This record is dominated by grants: $105,000 of the $105,309 with a category attached, or 99.7%. Novocure Israel Ltd accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest. Among medical oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 5 payments — averaging $21,062 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Israel Ltd$105K
- Telix Pharmaceuticals$309
Across 10 payments — averaging $188,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Incyte Corporation$496K
What the payments were for
- Grants$105,000100%
- Food & beverage$3090%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Israel Ltd | 1 | $105,000 |
| Telix Pharmaceuticals | 4 | $309 |
How this compares
$105,309 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $8,110 |
| Methylphenidate ErMethylphenidate Hcl | 20 | $2,164 |
| Lacosamide | 19 | $1,970 |
| Levetiracetam | 51 | $1,290 |
| Dexamethasone | 41 | $603 |
| Prochlorperazine Maleate | 15 | $408 |
| Escitalopram Oxalate | 19 | $222 |
| Gabapentin | 14 | $140 |
| Ondansetron Hcl | 18 | $106 |
| Mirtazapine | 11 | $64 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $61 |
| Lorazepam | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
- Bruce RothSaint Louis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.